Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis

Hepatitis C virus (HCV) infection is a major risk factor for liver cirrhosis and hepatocellular carcinoma (HCC), and is a leading cause of liver-related deaths worldwide. Recently available direct-acting antiviral agent is very safe and highly effective (>95% sustained virologic response, SVR) ag...

Full description

Saved in:
Bibliographic Details
Published inClinical and molecular hepatology Vol. 25; no. 3; pp. 234 - 244
Main Authors Seong Kyun Na, Byung-cheol Song
Format Journal Article
LanguageKorean
Published 대한간학회 30.09.2019
Subjects
Chronic hepatitis C
Hepatocellular carcinoma
Sustained virologic response
Online AccessGet full text

Cover

More Information
Summary:Hepatitis C virus (HCV) infection is a major risk factor for liver cirrhosis and hepatocellular carcinoma (HCC), and is a leading cause of liver-related deaths worldwide. Recently available direct-acting antiviral agent is very safe and highly effective (>95% sustained virologic response, SVR) against all genotypes of HCV. Achievement of SVR has been associated with a significant reduction of hepatic decompensation, development of HCC, and liver-related mortality. However, HCC risk is not eliminated even after SVR. The annual incidences of HCC in advanced fibrosis or cirrhosis have been estimated to be up to 2.5-4.5% even in patients with SVR. Therefore, surveillance for HCC is recommended in this high-risk patients. In this review, we will describe the clinical outcomes and the risk of HCC in patients with SVR and suggest who should receive surveillance for HCC. (Clin Mol Hepatol 2019;25:234-244)
Bibliography:The Korean Association for the Study of the Liver
ISSN:2287-2728
2287-285X